Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 4, 2000, Pages 345-349

  Friedman, Henry S ^a   Castellino, Robert C ^a   Elion, Gertrude B ^a   Keir, Stephen T ^a   Houghton, Peter J ^b   Johnson, Stewart P ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

CPT 11; Glioma; Nitrosourea

Indexed keywords

CARMUSTINE; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRADING; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; CONTRAST ENHANCEMENT; CONTROLLED STUDY; COVALENT BOND; DNA SYNTHESIS INHIBITION; DRUG EFFECT; GLIOMA; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 0034017444     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050050     Document Type: Article

References (23)

1. 1. Bleyer WA (1992) The impact in the United States and the world of center nervous system cancer during childhood. In: Packer RJ, Bleyer WA, Pochedly C (eds) Pediatric neuro-oncology. Harwood Academic Publishers, Philadelphia, p 1
2. 2. Bullard DE, Bigner DD (1979) Heterotransplantation of human craniopharyngiomas in athymic "nude" mice. Neurosurgery 4: 308
3. 3. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multi-disciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52: 997
4. 4. Coggins CA, Elion GB, Houghton PJ, Hare CB, Keir S, Colvin OM, Bigner DD, Friedman HS (1998) Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol 41: 485
5. 5. Fine HA (1994) The basis for current treatment recommendations for malignant gliomas. J Neurooncol 20: 111
6. 6. Friedman HS, Colvin OM, Skapek SX, Ludeman SM, Elion GB, Schold SC Jr, Jacobsen PF, Muhlbaier LH, Bigner DD (1988) Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 48: 4189
7. 7. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughesy T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley DM, Malczyn J, Elfring GL, Miller LL (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17: 1516
8. 8. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10: 16
9. 9. Garrett MJ, Hughes HJ, Freeman LS (1978) A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma. Clin Oncol 4: 71
10. 10. Giard DJ, Aronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417
11. 11. Green SB, Byar DP, Walker MD, Pistenman DA, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, Mealey J Jr, Odom GL, Paoletti P, Ransohoff J II, Robertson JT, Selker RG, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA (1983) Comparisons of carmustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67: 121
12. 12. Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, Bigner DD, Friedman HS (1997) Therapeutic efficacy of topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 39: 187
13. 13. Houghton PJ, Cheshire PJ, Hallman JC, Bissery MC, Mathieu-Boue A, Houghton JA (1993) Therapeutic efficacy of topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino-carbonyloxy-camptothecin against human tumor xenografts: lack of cross resistance in vivo in tumors with acquired resistance to topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 53: 2823
14. 14. Houghton PJ, Cheshire PJ, Hallman JD II, Lutz L, Friedman HS, Danks MK, Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393
15. 15. Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, Nutik S, Gutin PH, Wilson CB (1985) Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg 63: 218
16. 16. Levin VA, Wara WM, Davis RL, Silver P, Resser KJ, Yatsko K, Nutik S, Gutin PH, Wilson CB (1986) Northern California Oncology Group protocol 6G91: response to treatment with radiation therapy and seven-drug chemotherapy in patients with glioblastoma multiforme. Cancer Treat Rep 70: 739
17. 17. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18: 321
18. 18. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S, Ota K (1990) An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907
19. 19. Shapiro WR (1986) Therapy of adult malignant brain tumors. What have the clinical trials taught us? Semin Oncol 13: 38
20. 20. Slichenmyer WJ, Rowinsky EK, Grochow LB, Kaufmann SH, Donehower RC (1994) Camptothecin analogues: studies from The Johns Hopkins Oncology Center. Cancer Chemother Pharmacol 34: 53
21. 21. Solero CL, Monfardini S, Brambilla C, Vaghi A, Valagussa P, Morello G, Bonadonna G (1979) Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials 2: 43
22. 22. Von Hoff DD, Burris HA III, Eckardt J, Rothenberg M, Fields SM, Chen SF, Kuhn JG (1994) Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 34: 41
23. 23. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J II, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323